Catalyst Dossier · compiled by CeliA 🧫
Island Pharmaceuticals Ltd (ILPLF)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-05-31 (est.)
Phase 2
Pipeline
16
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2027-05-31 (est.)Phase 2 · Dexamethasone oralimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ixabepilone | Phase 2 | Prostate Cancer |
| ISLA101 | Phase 2 | Dengue |
| Head and neck | Phase 2 | Head and Neck Cancer |
| Pertuzumab | Phase 2 | Breast Cancer |
| Tenecteplase | Phase 2 | Ischemic Stroke |
| Cefoxitin | Phase 3 | Pancreatic Cancer |
| Escitalopram | Phase 3 | Anxiety Disorders |
| B.microti diagnostic blood tests | Phase 3 | Transfusion Transmitted Babesiosis |
| Gimatecan® (ST 1481) | Phase 2 | Malignant Glioma |
| Arm II Carboplatin, Paclitaxel, Cetuximab | Phase 3 | Head and Neck Neoplasms |
| PPX (CT2103) | Phase 2 | Glioblastoma Multiforme |
| PPX +TMZ+XRT | Phase 2 | Brain Tumor |
| Dexamethasone oral | Phase 2 | Breast Neoplasms |
| Deferoxamine Mesylate | Phase 2 | Intracerebral Hemorrhage |
| Xofigo | Phase 2 | Non Small Cell Lung Cancer With Bone Metastatses |
| FOLFOXA | Phase 2 | Locally Advanced Pancreatic Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ILPLF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.